Brokerages Anticipate Prothena Corporation PLC (NASDAQ:PRTA) Will Announce Quarterly Sales of $12.87 Million
Analysts predict that Prothena Corporation PLC (NASDAQ:PRTA) will report $12.87 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Prothena Corporation PLC’s earnings, with estimates ranging from $330,000.00 to $30.30 million. Prothena Corporation PLC reported sales of $330,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 3,800%. The business is scheduled to issue its next earnings results on Tuesday, August 1st.
On average, analysts expect that Prothena Corporation PLC will report full year sales of $12.87 million for the current year, with estimates ranging from $4.00 million to $31.20 million. For the next fiscal year, analysts expect that the firm will report sales of $43.97 million per share, with estimates ranging from $1.56 million to $101.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Prothena Corporation PLC.
Prothena Corporation PLC (NASDAQ:PRTA) last issued its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.33. Prothena Corporation PLC had a negative return on equity of 39.67% and a negative net margin of 16,012.49%. The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.26 million. During the same period last year, the business earned ($0.81) EPS. The business’s revenue was down 3.7% on a year-over-year basis.
A number of equities research analysts have recently commented on PRTA shares. Oppenheimer Holdings, Inc. set a $70.00 target price on Prothena Corporation PLC and gave the stock a “buy” rating in a research note on Thursday, April 6th. ValuEngine raised Prothena Corporation PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Tuesday, May 16th. Wedbush reissued an “outperform” rating and issued a $77.00 target price on shares of Prothena Corporation PLC in a research note on Monday, April 3rd. Finally, Jefferies Group LLC started coverage on Prothena Corporation PLC in a research note on Monday, July 10th. They issued a “buy” rating and a $100.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Prothena Corporation PLC currently has an average rating of “Buy” and a consensus target price of $77.07.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/16/brokerages-anticipate-prothena-corporation-plc-nasdaqprta-will-announce-quarterly-sales-of-12-87-million.html.
In other news, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the company’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $52.25, for a total value of $261,250.00. Following the transaction, the insider now directly owns 3,000 shares in the company, valued at $156,750. The disclosure for this sale can be found here. Corporate insiders own 3.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can increased its position in shares of Prothena Corporation PLC by 6.7% in the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after buying an additional 117 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of Prothena Corporation PLC during the first quarter worth about $167,000. Stifel Financial Corp acquired a new position in shares of Prothena Corporation PLC during the first quarter worth about $224,000. Karp Capital Management Corp acquired a new position in shares of Prothena Corporation PLC during the first quarter worth about $243,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Prothena Corporation PLC during the first quarter worth about $273,000.
Shares of Prothena Corporation PLC (PRTA) traded up 2.20% during trading on Friday, reaching $63.66. The company’s stock had a trading volume of 292,557 shares. Prothena Corporation PLC has a one year low of $35.04 and a one year high of $68.18. The stock’s 50 day moving average is $53.94 and its 200 day moving average is $52.72. The firm’s market cap is $2.42 billion.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.